Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antipsychotics Clear all
Withdrawn Phase 2 Interventional

Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia

NCT00425815
View directory record Official record
Conditions
Schizophrenia
Interventions
Org 24448, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 25, 2026, 4:11 PM EDT
Terminated Phase 2 Interventional Results available

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

NCT04421456
View directory record Official record
Conditions
Schizophrenia
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Garden Grove, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Results available

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

NCT00306475
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Divalproex Sodium Extended-Release Tablets, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

NCT02504476
View directory record Official record
Conditions
Schizophrenia or Schizoaffective Disorder
Interventions
AMG 581, Placebo, Midazolam
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 25, 2026, 4:11 PM EDT
Withdrawn Phase 3 Interventional

Zyprexa and Task Engagement in Schizophrenia

NCT00440843
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine (Zyprexa), Typicals
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Oct 25, 2026, 4:11 PM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 25, 2026, 4:11 PM EDT
Completed No phase listed Observational

Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment

NCT00538122
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
24 Holter Monitor Recording
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

NCT03818256
View directory record Official record
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Interventions
Miricorilant, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 4:11 PM EDT
Terminated Not applicable Interventional Results available

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

NCT02717130
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Columbia, Missouri • Kansas City, Missouri • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers

NCT01931059
View directory record Official record
Conditions
Imaging of the Brain and Antipsychotics, Neuronal Network Changes
Interventions
Risperidone, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 25, 2026, 4:11 PM EDT
Recruiting Phase 3 Interventional

Randomized Withdrawal Study in Patients With Schizophrenia

NCT06961968
View directory record Official record
Conditions
Schizophrenia
Interventions
iloperidone, placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Rogers, Arkansas • Costa Mesa, California • Lemon Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

NCT02824055
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO5545965
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Garden Grove, California • Glendale, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Not applicable Interventional Results available

A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness

NCT02085447
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Medication Adherence, Medication Non-Adherence
Interventions
CAE-L
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Not applicable Interventional Results available

Vitamin D Supplementation in Psychiatric Illnesses

NCT01004354
View directory record Official record
Conditions
Obesity, Vitamin D Deficiency, Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
Ergocalciferols
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 25, 2026, 4:11 PM EDT
Recruiting Phase 3 Interventional

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

NCT06482554
View directory record Official record
Conditions
Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions
Lumateperone 42 mg, Risperidone 2 mg
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 25, 2026, 4:11 PM EDT
Completed No phase listed Observational

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

NCT01181960
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Risperidone long acting injectable - New Starts, Risperidone long acting injectable - Continuous Users, Paliperidone Palmitate -New and Continuous Users, Other Antipsychotics - New Starts
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
34
States / cities
Bullhead City, Arizona • Colton, California • Imperial, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 25, 2026, 4:11 PM EDT
Recruiting Phase 4 Interventional

Exercise and Olanzapine-samidorphan

NCT06740890
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
Interventions
Olanzapine-samidorphan + exercise
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Not applicable Interventional Results available

The Family VOICE Study

NCT01804582
View directory record Official record
Conditions
Autism, Aggression, Bipolar Disorder, Psychotic Disorders
Interventions
Family Navigator consultation
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
2 Years to 15 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 25, 2026, 4:11 PM EDT
Terminated Phase 3 Interventional

Gabapentin for the Treatment of Neuroleptic-Induced Tremor

NCT00533455
View directory record Official record
Conditions
Neuroleptic-Induced Tremor
Interventions
Gabapentin
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 24, 2007 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

NCT02970305
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Phoenix, Arizona • Rogers, Arkansas • Bellflower, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 25, 2026, 4:11 PM EDT
Recruiting Phase 4 Interventional

CLOZAPINE Response in Biotype-1

NCT04580134
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Interventions
clozapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

NCT01192880
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Bitopertin, Antipsychotics
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 25, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

NCT00178932
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
genetic analysis, genetic assay
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 25, 2026, 4:11 PM EDT